Pancreatic Cancer Research

Clinical trialPhase 3Terminated

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

NCT01836432↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Stopped earlyCompany decision (Business decision)
Phase
Phase 3
Status
Terminated
Study type
Interventional
Start
May 2013
Expected end
24 March 2017
Enrollment
302 participants
Sites
32
Primary outcomes
Overall Survival
Sponsor
Industry
Results posted
No
Last update
28 May 2020

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 1